MDM2 and medulloblastoma: Based on these observations and previous work where we demonstrated that pharmacologically inhibiting MDM2 in medulloblastoma cells with wildtype TP53 reactivated p53 activity, it may be advantageous to investigate possible synergies between JQ1 and MDM2 inhibitors, such as nutlin-3 [32].